NCT03114527View on ClinicalTrials.gov

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 8, 2017

Primary Completion Date

November 12, 2020

Study Completion Date

December 31, 2025

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

Ribociclib

Orally bioavailable, highly selective small molecule inhibitor of CDK4/6

DRUG

Everolimus

mTOR inhibitor

Trial Locations (2)

19111

Fox Chase Cancer Center, Philadelphia

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Fox Chase Cancer Center

OTHER